National Guideline Clearinghouse | Epithelial ovarian, fallopian tube, and primary peritoneal cancer - Alberta, Canada

Blogger's Note: note the differences in early stage recommendations per cell type

National Guideline Clearinghouse | Epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Guideline Title

Epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Bibliographic Source(s)

 

Alberta Provincial Gynecologic Oncology Tumour Team. Epithelial ovarian, fallopian tube, and primary peritoneal cancer. Edmonton (Alberta): Alberta Health Services, Cancer Care; 2010 Jul. 19 p. (Clinical practice guideline; no. GYNE-005).  [104 references]

Guideline Status

This is the current release of the guideline.

- Scope Methodology Recommendations Evidence Supporting the Recommendations Benefits/Harms of Implementing the Guideline Recommendations

- Qualifying Statements Implementation of the Guideline Institute of Medicine (IOM) National Healthcare Quality Report Categories Identifying Information and Availability Disclaimer

Back to top

Scope

Disease/Condition(s)

• Epithelial ovarian cancer
• Fallopian tube cancer
• Primary peritoneal cancer

Guideline Category

Evaluation Management Treatment

Clinical Specialty

Obstetrics and Gynecology Oncology Radiation Oncology Surgery

Intended Users

Physician Assistants Physicians

 

Guideline Objective(s)

To outline management decisions for women with epithelial ovarian, fallopian tube, or primary peritoneal cancer



Key Points

1. Completely staged, early epithelial ovarian, fallopian tube, and primary peritoneal cancers are highly curable. As such, patients should be referred to a gynecologic oncologist for adequate staging, including sampling of para-aortic and pelvic lymph nodes, infracolic omentectomy, possible appendectomy and biopsy of suspicious peritoneal lesions, in addition to a thorough inspection and palpation of all peritoneal surfaces, and peritoneal washings.
2. Advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers are best treated with optimal debulking surgery in conjunction with adjuvant therapy. As such, patients should be referred to a gynecologic oncologist